Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue 5, 2001, Pages 443-448

  Mulligan, Kathleen ^a,b   Tai, Viva W ^b   Algren, Heather ^b   Abrams, Donald I ^a,b   Leiser, Roslyn J ^b   Lo, Joan C ^a,b   Schambelan, Morris ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Body composition; DEXA; Fat distribution; Lipodystrophy; Nucleoside analog reverse transcriptase inhibitors; Protease inhibitors; Wasting syndrome

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; BODY COMPOSITION; BODY FAT; CONTROLLED STUDY; DRUG INDUCED DISEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID STORAGE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; WASTING SYNDROME;

EID: 0035870550     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200104150-00006     Document Type: Article

References (24)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
2. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998;351: 871-5.
3. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998;351:1881-3.
4. Lo JC, Mulligan K, Tai VW, et al. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998;351:867-70.
5. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999;13:465-71.
6. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659-67.
7. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:F25-32.
8. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14:37-49.
9. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-1316.
10. Brinkman K, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-15.
11. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9.
12. Mulligan K, Tai VW, Schambelan M. Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997;5:43-8.
13. Paton N, Macallan D, Jebb S, et al. Longitudinal changes in body composition measured with a variety of methods in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14: 119-27.
14. Carey DG, Jenkins AB, Campbell LV, et al. Abdominal fat and insulin resistance in normal and overweight women. Diabetes 1996;45:633-8.
15. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20: 228-37.
16. Hadigan C, Corcoran C, Klibanski A, et al. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: Relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab 2000;85:35-41.
17. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999;13:1933-42.
18. Wanke C, Silva M, Knox TA, et al. Weight loss and wasting remain common complications in individuals infected with HIV in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;31:803-5.
19. Engelson ES, Kotler DP, Tan YX, et al. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr 1999;9: 1162-9.
20. Lichtenstein K, Ward D, Delaney K, et al. Clinical factors related to the severity of fat redistribution in the HIV outpatient study (HOPS) [abstract 23]. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, U.S.A., January 30 to February 2, 2000.
21. Martinez E, Perez B, Garcia A, et al. Risk factors for developing lipodystrophy in patients receiving protease inhibitors [abstract 15]. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, U.S.A., January 30 to February 2, 2000.
22. + African American and Latino individuals from Harlem [abstract 27]. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, U.S.A., January 30 to February 2, 2000.
23. Muurahainen N, Santos G, Kleintop M, et al. Gender differences in HIV-associated adipose redistribution syndrome: an update [abstract 26]. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, U.S.A., January 30 to February 2, 2000.
24. Justman J, Smit E, Danoff A, et al. Body habitus assessments in HIV-infected women: a cross-sectional study [abstract 25]. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, U.S.A., January 30 to February 2, 2000.